Accelerated Development of Appropriate Patient Therapies a Sustainable Multi s...
Accelerated Development of Appropriate Patient Therapies a Sustainable Multi stakeholder Approach from Research to Treatment outcomes Sofia ref. 115890
Progress in the life sciences and related technologies offer great potential for therapeutic benefits to patients in need. However, major adaptations to current paradigms of bringing medicines to patients are required in order to...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
EUPATI
European Patients Academy on Therapeutic Innovation
11M€
Cerrado
ADVANCE
Accelerated Development of Vaccine benefit risk Collaborati...
11M€
Cerrado
ADVANCE
Accelerated Development of Vaccine benefit-risk Collaborati...
11M€
Cerrado
EHR4CR
Electronic Health Record systems for Clinical Research
17M€
Cerrado
EHR4CR
Electronic Health Record systems for Clinical Research
17M€
Cerrado
DYNAMO
Modelling and dynamic assessment of integrated health and ca...
5M€
Cerrado
Información proyecto ADAPT-SMART
Duración del proyecto: 31 meses
Fecha Inicio: 2015-09-02
Fecha Fin: 2018-04-30
Líder del proyecto
STICHTING LYGATURE
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Progress in the life sciences and related technologies offer great potential for therapeutic benefits to patients in need. However, major adaptations to current paradigms of bringing medicines to patients are required in order to realize that potential and to address important challenges in the healthcare ecosystem.
Against this background, several initiatives are exploring new pathways to market, collectively referred to as Medicines Adaptive Pathways to Patients (MAPPs).
The ADAPT-SMART consortium is aligning a limited number of major stakeholders eager to progress towards MAPPs implementation. It will act as a neutral collaborative platform that will engage industry, SMEs, regulators, Health Technology Assessment bodies (HTAs), payers, governments, clinicians and patients.
The ADAPT-SMART consortium will contribute to align understanding of the impact of MAPPs, to share learnings between all stakeholders, and to allow the field to actively work towards MAPPs implementation.
The impact of the ADAPT-SMART CSA will be a result of the delivery of
• actionable advice/recommendations to IMI on how to best leverage results from past/current projects;
• concrete proposals for future (IMI) projects;
• actionable advice/recommendations and information to other actors in the healthcare environment;
• synthesis of learnings from pilot projects and case studies with relevance to MAPPs;
• communication of CSA outcomes by way of publications and conference presentations.
This CSA will increase the probability of successful implementation of MAPPs and accelerate access to crucial therapies, thus improving the position of both the patients in need of novel treatments and the research-based pharmaceutical industry.